SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934 DATE OF REPORT: MARCH 27, 2003 TITAN PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) DELAWARE 0-27436 94-3171940 - ---------------------------- ------------------------ ------------------- (State or other jurisdiction (Commission File Number) (IRS Employer of incorporation) Identification No.) 400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO, CALIFORNIA 94080 - ------------------------------------------------------------------------------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (650) 244-4990 -------------- - -------------------------------------------------------------------------------- ITEM 5. OTHER EVENTS The registrant hereby incorporates by reference the press release dated March 27, 2003 attached hereto as Exhibit 99.1 ("Titan Reports Fourth Quarter And Year End 2002 Results"). ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS (c) Exhibits 99.1 Press Release - Titan Reports Fourth Quarter And Year End 2002 Results 2 - -------------------------------------------------------------------------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TITAN PHARMACEUTICALS, INC. By: /s/ Robert E. Farrell ------------------------------------------- Robert E. Farrell, Executive Vice President and Chief Financial Officer Dated: March 27, 2003 3 - --------------------------------------------------------------------------------